Meeting
2021 ASCO Annual Meeting
First-in-man phase I clinical trial evaluating TTI-101, an orally bioavailable, small molecule inhibitor of STAT3, in patients with advanced solid tumors.
Authors
Apostolia Maria Tsimberidou
The University of Texas MD Anderson Cancer Center, Houston, TX
Apostolia Maria Tsimberidou , Sofia de Achaval , Imran Alibhai , Ahmed Omar Kaseb
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Developmental Therapeutics—Molecularly Targeted Agents and Tumor Biology
Track
Developmental Therapeutics—Molecularly Targeted Agents and Tumor Biology
Sub Track
Small Molecules
Clinical Trial Registration Number
NCT03195699
Citation
J Clin Oncol 39, 2021 (suppl 15; abstr TPS3158)
DOI
10.1200/JCO.2021.39.15_suppl.TPS3158
Abstract #
TPS3158
Poster Bd #
Online Only
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Annual Meeting
Phase 1 trial evaluating TTI-101, a first-in-class, orally bioavailable, small molecule, inhibitor of STAT3, in patients with advanced solid tumors.
First Author: Apostolia Maria Tsimberidou
Poster
2024 ASCO Annual Meeting
A phase 1, first-in-human study of CUSP06, a cadherin-6 (CDH6) -directed antibody-drug conjugate, in patients with platinum-refractory/resistant ovarian cancer and other advanced solid tumors.
First Author: Alexander I. Spira
Poster
2024 ASCO Gastrointestinal Cancers Symposium
A phase 1b/2 study to evaluate the safety and efficacy of TTI‑101 as monotherapy and in combination in advanced hepatocellular carcinoma.
First Author: Farshid Dayyani
Poster
2023 ASCO Annual Meeting
Phase 1 study evaluating the safety, tolerability, pharmacokinetics (PK), and efficacy of GEC255, a novel KRASG12C inhibitor, in advanced solid tumors.
First Author: Yan Zhang